Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > Wangbang phase 1

<< Previous

Bullboard Posts

Next >>

Comment by bazooka73on Dec 03, 2021 9:50am

111 Views

Post# 34194261

RE:RE:Wangbang phase 1

Pareto8020 wrote: That's even worse - it took them 3-4 years to even start the Phase I then??

Either way you slice it Wanbang is taking their sweet time and it obviously isn't a priority for them based on the snails pace they've been working on SBM's SGLT2 compound. I would have much rather seen a North Am company run with it - less risk and more exposure.

totally agree. The Wanbang "collaboration" turns out to be an absolute mess!

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market